CVS Health Aktie News

CVS remains a great Buy here, driven by the raised FY2025 adj EPS guidance and the robust outperformance against its healthcare peers despite the industrywide headwinds. Margin recovery is expected to accelerate from FY2026, supported by the Medicare Advantage four-star ratings, the upcoming ACA exit, and the repricing of group MA contracts. CVS' valuations remain discounted at current levels, ...

New report highlights the company's role as a top U.S. employer, investing in improving health and supporting local communities WOONSOCKET, R.I. , Dec. 5, 2025 /PRNewswire/ -- CVS Health® (NYSE: CVS) today released its inaugural National Economic Impact Report demonstrating the positive economic impact that the company has in communities across the country.

Bundling medical procedures and pharmaceutical medications into one prior authorization Implementing end-to-end generative AI capabilities into Aetna Health app HARTFORD, Conn. , Dec. 4, 2025 /PRNewswire/ -- Aetna®, a CVS Health® company (NYSE: CVS), today announces key milestones in support of the company's comprehensive strategy announced in June to remove friction in the healthcare system an...

HCA Healthcare is posting excellent results while continuing to implement a strategy that should drive a strong performance over the next 10 years. CVS Health is gradually implementing changes that will help it put the weak bottom-line performances of the past few years behind it.

John Buckingham, editor of the Prudent Speculator, reminds investors to be “willing to stomach volatility.”

CVS Health will pay $37.76 million to settle allegations it dispensed too many insulin pens to patients and then sought reimbursement from government healthcare programs, U.S. Attorney Jay Clayton in Manhattan said on Tuesday.

HUNTINGTON, W.Va. , Dec. 1, 2025 /PRNewswire/ -- Cornerstone Community Development, in cooperation with Winterwood, CVS Health® (NYSE: CVS) and other community organizations, invites the public and media to a special event celebrating the transformation of one of Huntington's most historic properties.

Harrow, Inc. is experiencing explosive growth, driven by its success in branded pharmaceuticals, especially Vevye. Vevye, HROW's flagship dry eye drug, is projected to reach $100M in 2025 and $300M in 2026, with potential for $2B+ by 2030. HROW's financials are accelerating: FCF/share expected at $4 in 2026 and $10 in 2027, with leverage rapidly declining and EBITDA margins rising.